Mild Cognitive Impairment (MCI)
Also known as: Mild Cognitive Impairment(MCI) / Mild Cognitive Impairment / Cognitive Impairment, Mild / Mild Cognitive Impairments / Cognitive Impairments, Mild / Mild neurocognitive disorder due to known physiological condition / Mild cognitive impairment of uncertain or unknown etiology / Mild neurocognitive disorder (disorder) / Mild Neurocognitive Disorder
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB12274 | Aducanumab | A monoclonal antibody indicated in the treatment of Alzheimer's disease. |
| DB14580 | Lecanemab | An amyloid beta-targeting antibody used to treat Alzheimer’s Disease in patients with mild cognitive impairment or mild dementia with a known amyloid beta pathology. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB12274 | Aducanumab | Amyloid beta A4 protein | target |
| DB14580 | Lecanemab | Amyloid beta A4 protein | target |